Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 months ago Solid tumor

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

mRNA Vaccine

Tumor immunotherapy, as an emerging method for diagnosing and treating tumors, has garnered widespread attention since its inception. Prior to the advent of tumor immunotherapy, the clinical treatment of solid tumors relied solely on traditional surgical removal, radiotherapy, and chemotherapy. Although these methods were effective, they came with significant drawbacks such as drug side effects and the risk of recurrence.

Since the 1990s, mRNA vaccines have been considered therapeutic vaccines. During the COVID-19 pandemic in 2020, mRNA vaccines were used in clinical treatments, saving countless lives. Today, as the advantages of mRNA vaccines are gradually being discovered, they are now applied in multiple fields.

The advent of China’s first self-replicating mRNA vaccine JCXH-211 undoubtedly marks a new breakthrough in the clinical diagnosis and treatment of various solid tumors in China.

What is the mRNA Vaccine JCXH-211?

JCXH-211 is the world’s first self-replicating RNA drug encoding human interleukin-12 (IL-12) to enter clinical trials. This srRNA vaccine delivers mRNA encoding IL-12 into the cytoplasm, continuously expressing IL-12 to enhance the body’s immune response against tumor cells.

In preclinical studies involving various mouse and PDX disease models, JCXH-211 has shown the ability to effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. Comprehensive GLP toxicology studies have also demonstrated good safety.

JCXH-211 has a broad range of indications and is expected to effectively treat multiple solid tumors. The anticipated prospects are as follows:

1. Lung Cancer:

As one of the leading causes of cancer death worldwide, lung cancer is often diagnosed at a late stage due to difficulties in early detection. JCXH-211, through continuous expression of IL-12 and activation of immune cells, is expected to effectively control the growth and spread of lung cancer cells.

2. Colorectal Cancer:

Current clinical treatments for colorectal cancer primarily involve surgery and radiotherapy/chemotherapy, which can remove visible tumors but have a high recurrence rate. Periodic administration of JCXH-211 may significantly reduce recurrence and improve patient survival.

3. Soft Tissue/Chondrosarcoma:

These tumors are highly invasive and cover a wide range of areas, often affecting surrounding soft tissues and progressing rapidly. Current treatments are limited to surgery and radiotherapy/chemotherapy, which, although somewhat effective, are not thorough, leading to high recurrence rates. JCXH-211 could become a new treatment method, enhancing the body’s immune response to combat these stubborn cancer cells.

4. Skin Cancer:

Clinical treatments for skin cancer mainly include surgery and radiotherapy. While most skin cancers have a good prognosis, the effects on intractable melanoma are poor. The expression of IL-12 can activate specific T cells, greatly aiding in the elimination of melanoma cells.

High-Efficiency Activation and Safety of the mRNA Vaccine JCXH-211!

mRNA vaccines not only encode antigens to induce specific immune responses against tumors but also possess inherent immunostimulatory properties. This dual mechanism allows JCXH-211 to activate the immune system more efficiently, enhancing the overall anti-tumor effect.

Moreover, the safety of mRNA vaccines is well-recognized. Since DNA is the genetic material of most species, including humans and viruses, and is transcribed into mRNA before being translated into proteins to perform functions in the body, injecting mRNA into the human body does not enter the cell nucleus, thereby eliminating the risk of genomic insertion mutations. Additionally, mRNA can be naturally degraded and excreted from the body, preventing accumulation. Thus, JCXH-211 presents lower potential risks and is safer.

Currently, clinical trials are progressing steadily. With the rapid advancement of tumor immunotherapy, JCXH-211 is expected to become a standard treatment for various solid tumors, offering hope to many cancer patients.

To assess whether the condition is suitable for cancer vaccine or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

2 months ago Solid tumor

Breakthrough in mRNA Cancer Vaccine! Chinese Medical Team Brings New Hope to Advanced Cancer Patients Resistant to Traditional Treatments

Cancer Vaccine

The rise of mRNA vaccines during the COVID-19 pandemic has inspired their use in cancer treatment. Recently, Professor Shen Baiyong’s team at Ruijin Hospital published a groundbreaking study in Cell Research. They reported the first therapeutic effects of an mRNA cancer vaccine targeting the KRAS G12V mutation in solid tumors globally, offering new hope to advanced cancer patients resistant to traditional treatments.

#### Research Highlights

Two patients with the KRAS G12V mutation and HLA-A*11:01 positivity were treated with the KRAS G12V mRNA vaccine and PD-1 inhibitors.

– First Case: An 86-year-old woman with pancreatic cancer showed significant lesion reduction and improved quality of life after treatment.

– Second Case: A 69-year-old man with advanced lung cancer experienced partial tumor regression and no notable side effects after treatment.

#### Significance

This study highlights the efficacy of mRNA cancer vaccines in treating advanced solid tumors. The KRAS G12V mutation has strong binding affinity with HLA-A11:01, common in Asians, suggesting many could benefit from this therapy.

Professor Shen, who leads the Pancreatic Disease Treatment Center at Ruijin Hospital, focuses on comprehensive pancreatic cancer care and has initiated clinical trials on mRNA vaccines for advanced patients.

#### Clinical Trials

Ruijin Hospital is conducting trials on fixed single-target, multi-target personalized, and postoperative preventive mRNA vaccines, promising new hope for patients. For more information, please contact us.

This innovative research could bring new treatment options to more patients worldwide.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CancerResearch #mRNAVaccine #MedicalBreakthrough #AdvancedCancer #InnovativeTreatment #Healthcare #Oncology #ChineseMedicalTeam #NewHope #CancerTreatment #CellResearch

5 months ago CAR-T

🎉💉 Exciting Breakthrough Alert! Chinese Medical Team Unveils Game-Changing mRNA Cancer Vaccine 🎉💉

Advanced Science

Say hello to the future of cancer treatment! A groundbreaking mRNA cancer vaccine jointly developed by Chinese scientists has hit the spotlight, promising to elevate tumor suppression rates and extend survival periods.

🔬 What’s the Buzz? 🔬
Published in the prestigious journal “Advanced Science”, the research titled “All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer” reveals a novel mRNA cancer vaccine. This vaccine, packaged with lipid nanoparticles (LNPs), delivers All-Trans-Retinoic Acid (ATRA) and mRNA, effectively stimulating mucosal immune responses in the intestines. Compared to conventional mRNA-LNP vaccines, this innovative approach significantly boosts tumor suppression and prolongs survival rates.

🩺 Why It Matters 🩺
Colorectal cancer ranks third in cancer incidence and second in mortality globally. Conventional treatments such as surgery, chemotherapy, and radiation often come with high recurrence rates. Enter cancer immunotherapy—the beacon of hope in the fight against colorectal cancer. Cancer vaccines, a vital component of immunotherapy, harness the body’s immune system to target and destroy cancer cells. With the recent success of mRNA vaccines for COVID-19, mRNA cancer vaccines have garnered immense attention for their potential to revolutionize cancer treatment.

🚀 The Breakthrough 🚀
The key lies in ATRA-LNP’s ability to induce cytotoxic T cells in the intestines, offering a promising therapeutic approach for colorectal cancer. In animal models, ATRA-LNP treatment led to a remarkable reduction in tumor growth and extended survival rates compared to conventional treatments. These findings underscore the potential of mRNA cancer vaccines, particularly in enhancing the treatment outcomes for colorectal cancer patients.

🌟 The Takeaway 🌟
With its ability to activate anti-tumor immune responses at mucosal surfaces, the novel mRNA cancer vaccine brings hope for improved outcomes in colorectal cancer treatment. ATRA incorporation into LNPs not only enhances mRNA delivery efficiency but also directs activated T cells towards the intestines, amplifying their anti-tumor effects. This study paves the way for a promising future in enhancing the efficacy of mRNA cancer vaccines against colorectal cancer.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: 137 1795 9070

#CancerResearch #MedicalBreakthrough #ImmunotherapyInAction #ColorectalCancerFighters #mRNA #CancerVaccine #vaccine #colorectal #colorectalcancer #cancerfighters #chinesemedical #cancertreatment #tumor

7 months ago CAR-T

Putin Says Russia Is Close to Creating Cancer Vaccines. A Look at China’s Advancements

Putin

Recently, a viral piece of information has swept the internet. According to reports, Russian President Putin revealed that Russian scientists are close to developing a cancer vaccine and a new generation of immunomodulatory drugs, which can soon be made available to patients for effective personalized treatment.

However, Putin did not specify which type of cancer this vaccine would prevent or how it would prevent it. Nevertheless, this news has spread widely internationally, with some even exaggerating its effectiveness. So, is this really true?

It is reported that the information revealed by President Putin is indeed true and will soon be used for personalized treatment. It can be confirmed that this cancer vaccine is a therapeutic vaccine. However, it is not a treatment for all types of cancer but rather a “highly customized” vaccine based on a certain gene sequencing, targeting different mutation sites, including multiple sites, for each patient.

Cancer vaccines are a form of active immunotherapy and an important part of tumor immunotherapy. They work by stimulating or restoring the body’s own immune system to prevent cancer development or kill existing tumors. Cancer vaccines mainly include cell vaccines, DNA vaccines, mRNA vaccines, peptide vaccines, dendritic cell vaccines, nano vaccines, etc., and have shown promising clinical efficacy in the treatment of solid tumors such as malignant melanoma, lung cancer, ovarian cancer, and cervical cancer.

Cancer Vaccines

According to data from clinicaltrials.gov, China has about 150 ongoing tumor vaccine projects. China’s first mRNA tumor vaccine is targeting FDA approval, and more tumor mRNA vaccines are emerging, targeting lung cancer, pancreatic cancer, breast cancer, and more.

The personalized tumor neoantigen vaccine LK101 injection has been approved for clinical use!

On March 15, 2023, according to the official website of the National Medical Products Administration Drug Evaluation Center (CDE), the new drug clinical trial application (IND) of the personalized tumor neoantigen vaccine “LK101 injection” independently developed by Beijing Likang Life was approved for the treatment of advanced solid tumors.

It is reported that this product is the first domestically approved personalized tumor neoantigen vaccine to enter clinical stage and the first completely personalized mRNA editing product approved for clinical stage in China, marking a milestone event in the field of mRNA tumor vaccines in China.

On December 22, 2022, LK101 injection submitted a new drug clinical research application (IND) and was accepted. This personalized tumor neoantigen vaccine adopts the form of mRNA-DC (mRNA-dendritic cell) vaccine, which transfects dendritic cells with mRNA encoding tumor neoantigens ex vivo. The vaccine not only has high safety and good tolerance but also can provide patients with long-term anticancer effects.

Disease iNeo-Vac-P01 new antigen vaccine!

Personalized cancer vaccines significantly effective against a wide range of advanced solid tumors

The research team of Zhejiang Shao Yifu Hospital designed a peptide-based neoantigen vaccine iNeo-Vac-P01 and conducted a prospective clinical trial, enrolling a total of 22 patients with standard treatment failure and a wide range of advanced solid tumors. Using the iNeo artificial intelligence vaccine design platform, personalized peptide drug preparation and quality control system were used to customize iNeo-Vac-P01 vaccine for each patient.

After treatment, the results showed that among the 22 patients with advanced malignant tumors, 20 had no adverse reactions or had mild adverse reactions. The disease control rate was 71.4%, and the median progression-free survival was 4.6 months, with the median survival not yet reached.

The study suggests that for patients with advanced solid tumors, iNeo-Vac-P01 monotherapy is feasible and safe. It can induce T-cell-mediated immune responses against tumor neoantigens and may have good anti-tumor efficacy.

JCXH-211: Targeting multiple solid tumors with tumor neoantigen mRNA vaccine

Recently, a tumor neoantigen mRNA vaccine developed by Jiachen Xihai Biotechnology Co., Ltd. JCXH-211 has obtained FDA’s IND approval. JCXH-211 is a novel drug based on self-replicating mRNA encoding interleukin-12 (IL-12), which can express IL-12 in the body at a low dose for a long time and is suitable for the potential treatment of various advanced solid tumors.

Preclinical studies have shown that JCXH-211 can effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. This excellent tumor clearance effect is due to the strong antiviral immune response induced by RNA replicons and the strong antitumor immune response activated by IL-12. In comprehensive GLP toxicological studies, JCXH-211 has shown high safety.

The Phase 1 clinical trial of JCXH-211 will evaluate the efficacy of single-agent JCXH-211 in patients with advanced malignant solid tumors who have progressed or cannot tolerate existing treatments after receiving current treatment. This trial is open to patients aged 18 or older with at least one tumor lesion suitable for IT injection, measurable disease according to RECIST1.1, sufficient organ function, and an ECOG physical status of 0 to 1. Let’s wait and see its effectiveness!

#JCXH211 #cancer #CancerVaccine #ImmunotherapyBreakthrough #PersonalizedTreatment #TumorVaccine #mRNAVaccine #NeoantigenVaccine #CancerResearch #PrecisionMedicine #ClinicalTrials #MedicalInnovation

Menu

Tags Archives: mRNA

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~